An observational study in Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma and Recurrent Primary Peritoneal Carcinoma, sponsored by University of Washington. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by University of Washington · Observational
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
720 studies on the registry are indexed under Fallopian Tube Neoplasms; 127 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 233 across 70 observational studies indexed under Fallopian Tube Neoplasms.
Browse Fallopian Tube Neoplasms studies →University of Washington is the lead sponsor of 1,397 studies on the registry; 225 are open to participants now.
Of its 154 completed or terminated interventional studies of FDA-regulated products, 132 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects who have had ovarian, peritoneal, or fallopian tube cancer and have completed or plan to complete at least 5 cycles of platinum-based chemotherapy or subjects who have had a solid tumor diagnosis and have received at least 4 months of PARP inhibitor and/or been diagnosed with a blood disorder.
Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
OR
Subjects who have or have had a solid tumor diagnosis and any of the following:
Exclusion Criteria:
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
Other: Non-Interventional Study
Non-interventional study
Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients
Time frame: Through study completion, up to 5 years
Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors
Measurement Tool: will measure by BM biopsy confirmation done by local hematologist
Time frame: Through study completion, up to 5 years
Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN
Measurement Tool: the variant allele fraction of the blood clone
Time frame: Through study completion, up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Washington